Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 33 results.
User Information
Export Records
  1. 1.   Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection
  2. Happe, Myra; Lynch, Rebecca M; Fichtenbaum, Carl J; Heath, Sonya L; Koletar, Susan L; Landovitz, Raphael J; Presti, Rachel M; Santana-Bagur, Jorge L; Tressler, Randall L; Holman, LaSonji A; Novik, Laura; Roa, Jhoanna C; Rothwell, Ro Shauna; Strom, Larisa; Wang,Jing; Hu, Zonghui; Conan-Cibotti, Michelle; Bhatnagar, Anjali M; Dwyer, Bridget; Ko, Sung Hee; Belinky, Frida; Namboodiri, Aryan M; Pandey, Janardan P; Carroll, Robin; Basappa, Manjula; Serebryannyy, Leonid; Narpala, Sandeep R; Lin, Bob C; McDermott, Adrian B; Boritz, Eli A; Capparelli, Edmund V; Coates, Emily E; Koup, Richard A; Ledgerwood, Julie E; Mascola, John R; Chen, Grace L; Tebas, Pablo
  3. JCI Insight. 2025, Feb 24; 10(4):
  1. 2.   TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia
  2. Del Prete,Greg; Alvord, W Gregory; Li,Yuan; Deleage,Claire; Nag,Mukta; Oswald,Kelli; Thomas,James; Pyle,Cathi; Bosche,Bj; Coalter,Vicky; Wiles,Adam; Wiles,Rodney; Berkemeier,Brian; Hull,Mike; Chipriano, Elizabeth; Silipino,Lorna; Fast,Randy; Kiser,Jacob; Kiser,Rebecca; Malys,Tyler; Kramer,Josh; Breed,Matthew; Trubey,Charles; Estes,Jake; Barnes, Tiffany L; Hesselgesser, Joseph; Geleziunas, Romas; Lifson,Jeffrey
  3. JCI insight. 2019, Jun 06; 4(11): pii: 127717.
  1. 3.   Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells
  2. Caropreso, V.; Darvishi, E.; Turbyville, T. J.; Ratnayake, R.; Grohar, P. J.; McMahon, J. B.; Woldemichael, G. M.
  3. The Journal of biological chemistry. 2016, 6-May; 291(19): 10058-66.
  1. 4.   Configuration-dependent Presentation of Multivalent IL-15:IL-15Ralpha Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity
  2. Hong, E.; Usiskin, I. M.; Bergamaschi, C.; Hanlon, D. J.; Edelson, R. L.; Justesen, S.; Pavlakis, G. N.; Flavell, R. A.; Fahmy, T. M.
  3. The Journal of biological chemistry. 2016, 22-Apr; 291(17): 8931-50.
  1. 5.   Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells
  2. Reshma, R. S.; Sreelatha, K. H.; Somasundaram, V.; Satheesh Kumar, S.; Nadhan, R.; Nair, R. S.; Srinivas, P.
  3. Pharmacological Research. 2016, Mar; 105: 134-45.
  1. 6.   Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents
  2. Devkota, L.; Lin, C. M.; Strecker, T. E.; Wang, Y.; Tidmore, J. K.; Chen, Z.; Guddneppanavar, R.; Jelinek, C. J.; Lopez, R.; Liu, L.; Hamel, E.; Mason, R. P.; Chaplin, D. J.; Trawick, M. L.; Pinney, K. G.
  3. Bioorganic & Medicinal Chemistry. 2016, 1-Mar; 24(5): 938-56.
  1. 7.   Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium
  2. Gaudet, M. M.; Barrdahl, M.; Lindstrom, S.; Travis, R. C.; Auer, P. L.; Buring, J. E.; Chanock, S. J.; Eliassen, A. H.; Gapstur, S. M.; Giles, G. G.; Gunter, M.; Haiman, C.; Hunter, D. J.; Joshi, A. D.; Kaaks, R.; Khaw, K. T.; Lee, I. M.; Le March, L.; Milne, R. L.; Peeters, P. H.; Sund, M.; Tamimi, R.; Trichopoulou, A.; Weiderpass, E.; Yang, X. R.; Prentice, R. L.; Feigelson, H. S.; Canzian, F.; Kraft, P.
  3. Breast Cancer Research and Treatment. 2016, Feb; 155(3): 531-40.
  1. 8.   HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells
  2. Maldarelli, F.; Wu, X.; Su, L.; Simonetti, F. R.; Shao, W.; Hill, S.; Spindler, J.; Ferris, A. L.; Mellors, J. W.; Kearney, M. F.; Coffin, J. M.; Hughes, S. H.
  3. Science. 2014, 11-Jul; 345(6193): 179-83.
  1. 9.   Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis
  2. Bode, C.; Kinjo, T.; Alvord, W. G.; Klinman, D. M.
  3. Carcinogenesis. 2014, May; 35(5): 1078-83.
  1. 10.   Antiviral innate immunity: editorial overview
  2. Freed, E. O.; Gale, M.
  3. Journal of Molecular Biology. 2014, 20-Mar; 426(6): 1129-32.
  1. 11.   The importance of Raf dimerization in cell signaling
  2. Freeman, A. K.; Ritt, D. A.; Morrison, D. K.
  3. Small GTPases. 2013, Jul-Sep; 4(3): 180-5.
  1. 12.   Potential for therapeutic targeting of tumor stem cells
  2. Saini, V.; Shoemaker, R. H.
  3. Cancer Science. 2010, Jan; 101(1): 16-21.
  1. 13.   Targeting prostate cancer stem cells
  2. Crea, F.; Mathews, L. A.; Farrar, W. L.; Hurt, E. M.
  3. Anti-cancer agents in medicinal chemistry. 2009, Dec; 9(10): 1105-13.
  1. 14.   Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine
  2. Klinman, D. M.; Yamamoto, M.; Tross, D.; Tomaru, K.
  3. Expert Opinion on Biological Therapy. 2009, Dec; 9(12): 1477-86.
  1. 15.   Microbial antitumor drugs: natural products of microbial origin as anticancer agents
  2. Newman, D. J.; Cragg, G. M.
  3. Current Opinion in Investigational Drugs. 2009, Dec; 10(12): 1280-96.
  1. 16.   Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children
  2. Freeman, A. F.; Olivier, K. N.; Rubio, T. T.; Bartlett, G.; Ochi, J. W.; Claypool, R. J.; Ding, L.; Kuhns, D. B.; Holland, S. M.
  3. Pediatric pulmonology. 2009, Nov; 44(11): 1051-6.
  1. 17.   Development of HIF-1 inhibitors for cancer therapy
  2. Onnis, B.; Rapisarda, A.; Melillo, G.
  3. Journal of Cellular and Molecular Medicine. 2009, Sep; 13(9A): 2780-6.
  1. 18.   Virus maturation as a new HIV-1 therapeutic target
  2. Adamson, C. S.; Salzwedel, K.; Freed, E. O.
  3. Expert opinion on therapeutic targets. 2009, Aug; 13(8): 895-908.
  1. 19.   Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
  2. Adamson, C. S.; Freed, E. O.
  3. Molecular Interventions. 2009, Apr; 9(2): 70-4.
  1. 20.   Short and sweet: evolution of a small glycopeptide from a bladder disorder to an anticancer lead
  2. Barchi, J. J., Jr.; Kaczmarek, P.
  3. Molecular Interventions. 2009, Feb; 9(1): 14-7.
  1. 21.   RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy
  2. Shao, W.; Kearney, M.; Maldarelli, F.; Mellors, J. W.; Stephens, R. M.; Lifson, J. D.; KewalRamani, V. N.; Ambrose, Z.; Coffin, J. M.; Palmer, S. E.
  3. Retrovirology. 2009 6: 101.
  1. 22.   Identification and characterization of fully human anti-CD22 monoclonal antibodies
  2. Xiao, X.; Ho, M.; Zhu, Z.; Pastan, I.; Dimitrov, D. S.
  3. Mabs. 2009, May-Jun; 1(3): 297-303.
  1. 23.   Alarmins and antimicrobial immunity
  2. Yang, D.; Oppenheim, J. J.
  3. Medical Mycology. 2009 47(Suppl 1): S146-53.
  1. 24.   Eradication of HIV in infected patients: Some potential approaches
  2. Yang, Q. E.
  3. Medical Science Monitor. 2004, JUL; 10(7): RA155-RA165.
  1. 25.   HIV-1 induced in the setting of IL-2 therapy is transient and not derived from PBMC proviral reservoirs
  2. Imamichi, H.; Zhang, Y. M.; Kovacs, J.; Dewar, R.; Metcalf, J.; Vogel, S.; Salzman, N.; Lane, H. C.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 135 (abstract no. 358).
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel